Back to Lung Cancer
NCT00006231
NCT00006231
Who may be able to join
Who might be able to join this trial:
- You have been diagnosed with malignant pleural mesothelioma (a type of cancer affecting the lining of the lungs), confirmed by a tissue sample taken through a procedure such as a chest drain, fluid removal, biopsy, or camera examination of the chest within the last 3 weeks
- You are expected to live for at least 3 months
Who may not be able to join:
- You have previously received chemotherapy (cancer-fighting drugs given throughout the body) for mesothelioma
- You have previously received radiotherapy (radiation treatment) directed at the affected area for mesothelioma
- You have had, or are planning to have, any other invasive (surgical or procedural) treatment to the same area of the chest during the trial or within 1 year after the study ends
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Trial details
Status
Completed
Phase
Phase 3
Sponsor
University of Glasgow
Registry
clinicaltrials_gov
Start date
1 February 1998
Where this trial is recruiting
🇬🇧 United Kingdom
Primary endpoints
Incidence of metastatic skin nodules
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.